Scilex Holding Soars 20.81% on SEC Approval, Funding, Partnership

On August 14, 2025, Scilex Holding's stock price surged by 20.81% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

The recent surge in Scilex Holding's stock price can be attributed to several key developments. The Securities and Exchange Commission (SEC) announced the effectiveness of the Form S-4 registration statement for the business combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, which has been a major catalyst for the stock's performance. This merger proposal has generated considerable excitement among investors, as it represents a strategic move that could enhance the company's market position and growth prospects.

Additionally, Scilex Holding has secured $100 million in funding from Tumim Stone Capital, providing the company with the financial resources needed to pursue its strategic initiatives and expand its operations. This funding round has been well-received by the market, as it underscores the company's strong financial health and growth potential.

Furthermore, Scilex Holding has entered into an option agreement with Oramed Pharmaceuticals, which could open up new opportunities for the company in the pharmaceutical sector. This partnership is expected to drive innovation and growth, further bolstering investor confidence in the company's future prospects.